Clinical Trial Detail

NCT ID NCT04091750
Title Nivolumab/Ipilimumab Plus Cabozantinib in Patients With Unresectable Advanced Melanoma
Recruitment Recruiting
Gender both
Phase Phase II
Variant Requirements No
Sponsors Georgetown University
Indications

melanoma

Therapies

Cabozantinib + Ipilimumab + Nivolumab

Cabozantinib + Nivolumab

Age Groups: senior adult

No variant requirements are available.